Exponent, Inc.

Informe acción NasdaqGS:EXPO

Capitalización de mercado: US$3.0b

Exponent Dirección

Dirección controles de criterios 4/4

El CEO de Exponent es Catherine Corrigan , nombrado en May 2018, tiene una permanencia de 8.17 años. compensación anual total es $3.74M, compuesta por 26% salario y 74% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.24% de las acciones de la empresa, por valor de $7.16M. La antigüedad media del equipo directivo y de la junta directiva es de 10.2 años y 5.8 años, respectivamente.

Información clave

Catherine Corrigan

Chief Executive Officer (CEO)

US$3.7m

Compensación total

Porcentaje del salario del CEO25.96%
Permanencia del CEO8.2yrs
Participación del CEO0.2%
Permanencia media de la dirección10.2yrs
Promedio de permanencia en la Junta Directiva5.8yrs

Actualizaciones recientes de la dirección

Recent updates

Seeking Alpha Jul 07

Exponent: AI Makes The Work More Complex, Not Less Valuable

Summary Exponent Inc. receives a buy rating, driven by its expert consulting model in high-stakes, complex technical domains. EXPO’s value proposition lies in its deep technical talent, critical for problems where failure is costly and regulatory scrutiny is high. The AI debate is a catalyst: rising complexity in physical systems should increase demand for EXPO’s services, not diminish it. EXPO trades at ~24x NTM PE, appears historically cheap, and has upside if growth and margins outpace consensus as AI complexity accelerates. Read the full article on Seeking Alpha
Actualización de narrativa Jul 07

EXPO: Share Repurchases And Premium Services Will Support Future Returns

Analysts have reduced the Exponent price target to $80 from $95 and now see fair value closer to $75, reflecting a higher discount rate, a lower future P/E assumption, and a focus on companies with more visible growth drivers in the current small cap industrials group. Analyst Commentary on Exponent Recent research updates on Exponent highlight a more cautious tone, with a cut to the price target and removal from a conviction list signaling that some investors are prioritizing other opportunities in the current small cap industrials group.
Actualización de narrativa Jun 22

EXPO: AI Failure Analysis And Buybacks Will Support Premium Future P/E

Analysts have reduced their price target on Exponent to about $81.67 from $90, with recent target cuts to $80 citing macro uncertainty and a stronger preference for companies with resilient end markets and more visible growth drivers. Analyst Commentary Recent research on Exponent highlights a mix of optimism about the company’s positioning and caution around broader macro conditions, which is reflected in the reduced price targets around the US$80 level.
Actualización de narrativa Jun 07

EXPO: Resilient End Markets And Buybacks Will Support Future Earnings Quality

Analysts have reduced their price target on Exponent to $80 from $95, citing a preference for stocks with more resilient end markets and clearer growth drivers in the current small-cap industrials group. Analyst Commentary Recent research highlights that while the price target on Exponent has been adjusted to US$80 from US$95, the stock still sits on the preferred list within the smaller cap industrials group.
Actualización de narrativa May 23

EXPO: Buybacks And Resilient End Markets Will Support Future Earnings Quality

Analysts have trimmed their fair value estimate for Exponent to $90 from $95, reflecting lower price targets in recent research and a stronger emphasis on selectivity in smaller cap industrials. Analyst Commentary Recent research points to a more selective stance on smaller cap industrials, with Exponent still viewed as a quality exposure for investors who prioritize resilient demand and clear growth drivers.
Actualización de narrativa May 03

EXPO: AI Failure Analysis And Buybacks Will Support Higher Earnings Quality

Analysts have adjusted their view on Exponent with a modest change to the price target in the $5 range, reflecting updated assumptions on growth, profitability and a slightly higher future P/E multiple informed by recent mixed revisions from JPMorgan and UBS. Analyst Commentary Recent commentary around Exponent highlights a mix of caution and optimism, with price targets adjusted within a narrow range and opinions split on the risk and reward at current levels.
Actualización de narrativa Apr 18

EXPO: AI Failure Analysis Demand Will Support Higher Earnings Quality

Analysts have adjusted the 12 month price target on Exponent to $95 from $90, reflecting updated assumptions around revenue growth, profit margins, and the P/E multiple they are willing to apply to future earnings. Analyst Commentary Recent Street research on Exponent has centered on how much investors are willing to pay for the company’s future earnings, with price targets adjusted as analysts revisit revenue assumptions, profit margins, and the P/E multiple.
Actualización de narrativa Apr 04

EXPO: AI Failure Analysis Work Will Sustain Premium P/E And Shareholder Returns

Analysts have trimmed their average price target for Exponent by $1.67 to reflect slightly lower fair value and profit margin assumptions, while still applying a relatively high future P/E multiple informed by recent mixed price target moves from JPMorgan and UBS. Analyst Commentary Recent Street research on Exponent reflects a mix of optimism about the business model and caution around valuation and near term execution, which is why price targets have moved in both directions.
Actualización de narrativa Mar 21

EXPO: AI Failure Analysis Work Will Support Margins And Shareholder Returns

Analysts have lifted their 12 month price target on Exponent by about $6 to around $92. This reflects updated expectations around revenue, margins and a slightly lower future P/E multiple following recent research updates from major firms.
Actualización de narrativa Mar 07

EXPO: Buybacks And Dividend Increases Will Support Future Shareholder Returns

Analysts nudged their price target on Exponent higher by $4, citing slightly firmer growth and margin assumptions, along with a modestly lower future P/E outlook as key supports for the revised view. Analyst Commentary Recent research coverage around Exponent has centered on how much investors should be willing to pay for the company relative to its growth and margin profile.
Actualización de narrativa Feb 20

EXPO: Raised UBS Target And Buybacks Will Support Higher Future P/E

Analysts have raised their price target on Exponent by $4 to $85, citing updated assumptions that include slightly lower revenue growth, a modestly higher discount rate, improved profit margin expectations, and a higher future P/E multiple. Analyst Commentary Recent Street research around Exponent highlights a mix of optimism and restraint, with the latest published work focusing on valuation inputs, growth expectations, and how much investors are willing to pay for the stock through the P/E multiple.
Artículo de análisis Feb 09

Exponent (NASDAQ:EXPO) Is Increasing Its Dividend To $0.31

The board of Exponent, Inc. ( NASDAQ:EXPO ) has announced that the dividend on 20th of March will be increased to...
Actualización de narrativa Feb 06

EXPO: Bullish JPMorgan Initiation Will Support Confidence In Updated Fair Value Estimate

Analysts have raised their fair value estimate for Exponent from US$76.00 to US$81.00, citing updated assumptions for revenue growth, profit margins, and a slightly lower future P/E multiple in light of recent bullish Street research. Analyst Commentary Recent Street research, including a new bullish view from JPMorgan, has put more attention on how Exponent is priced and what could get in the way of the updated fair value estimate of US$81.00.
Actualización de narrativa Jan 23

EXPO: AI Failure Analysis Work Will Offset Automation Headwind Risks

Analysts have trimmed their price target on Exponent to US$90 from US$100, citing both the potential for increased AI driven failure analysis work and the offsetting risk that greater automation could reduce billable hours in consulting. Analyst Commentary Recent research points to a more balanced view on Exponent, with the reduced US$90 price target reflecting both potential upside from AI driven work and execution risks around automation in core consulting practices.
Actualización de narrativa Jan 09

EXPO: AI Failure Analysis Demand Will Support Future Consulting Engagements

Analysts have reduced their fair value estimate for Exponent to $90 from $100, citing a lower assumed future P/E multiple as they weigh the potential for AI-driven demand for failure analysis work against the risk that automation could reduce billable hours across the consulting sector. Analyst Commentary Recent commentary from bullish analysts centers on how AI adoption could shape Exponent's long term opportunity set, even as they factor in the risk that automation may cap billable hours across the consulting sector.
Artículo de análisis Jan 08

What Exponent, Inc.'s (NASDAQ:EXPO) P/E Is Not Telling You

Exponent, Inc.'s ( NASDAQ:EXPO ) price-to-earnings (or "P/E") ratio of 34.9x might make it look like a strong sell...
Actualización de narrativa Dec 16

EXPO: AI Failure Analysis Demand Will Outweigh Automation Efficiency Headwinds

Analysts have nudged their fair value estimate for Exponent higher to approximately $85.50 from $83.00 per share, citing the potential for AI driven demand in complex failure analysis work, while acknowledging that automation related efficiency gains could temper billable hours across the consulting industry. Analyst Commentary Bullish analysts highlight that the revised target still implies meaningful upside from current levels, even after a modest trim.
Actualización de narrativa Dec 01

EXPO: AI-Driven Demand Will Drive Future Engagements Despite Automation Headwinds

Analysts have revised Exponent's price target downward by $10 to $90 per share, citing potential opportunities from AI-driven engagements as well as industry headwinds related to automation efficiencies. Analyst Commentary Following the recent revision to Exponent's price target, analysts have highlighted both opportunities and risks facing the company in today's evolving market landscape.
Actualización de narrativa Nov 17

EXPO: AI-Driven Client Demand Will Offset Automation Concerns In Consulting

Exponent’s analyst price target has been reduced by $10 to $90, as analysts cite ongoing automation concerns that could impact the consulting sector. They also note potential opportunities from increased AI-driven client demand.
Artículo de análisis Nov 02

Exponent, Inc. Just Beat EPS By 8.5%: Here's What Analysts Think Will Happen Next

A week ago, Exponent, Inc. ( NASDAQ:EXPO ) came out with a strong set of third-quarter numbers that could potentially...
Actualización de narrativa Nov 02

EXPO: Increased Buyback Will Drive Shareholder Returns In Coming Quarters

Narrative Update: Exponent Analyst Price Target Adjustment Analysts have lowered their price target for Exponent from $88 to $83. This change reflects updated expectations for revenue growth and profitability margins moving forward.
Artículo de análisis Oct 06

Returns On Capital At Exponent (NASDAQ:EXPO) Have Stalled

If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'd...
Artículo de análisis Jul 30

A Look At The Fair Value Of Exponent, Inc. (NASDAQ:EXPO)

Key Insights Exponent's estimated fair value is US$63.97 based on 2 Stage Free Cash Flow to Equity Exponent's US$70.44...
Artículo de análisis Jul 14

When Should You Buy Exponent, Inc. (NASDAQ:EXPO)?

Exponent, Inc. ( NASDAQ:EXPO ), might not be a large cap stock, but it received a lot of attention from a substantial...
Artículo de análisis Jun 28

Exponent (NASDAQ:EXPO) Knows How To Allocate Capital

If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Ideally, a...
Artículo de análisis May 27

Subdued Growth No Barrier To Exponent, Inc.'s (NASDAQ:EXPO) Price

Exponent, Inc.'s ( NASDAQ:EXPO ) price-to-earnings (or "P/E") ratio of 36.7x might make it look like a strong sell...
Artículo de análisis Apr 06

Is Exponent, Inc. (NASDAQ:EXPO) Potentially Undervalued?

Exponent, Inc. ( NASDAQ:EXPO ), might not be a large cap stock, but it saw significant share price movement during...
Artículo de análisis Mar 22

Return Trends At Exponent (NASDAQ:EXPO) Aren't Appealing

If you're looking for a multi-bagger, there's a few things to keep an eye out for. In a perfect world, we'd like to see...
Seeking Alpha Mar 10

Exponent: A Unique Dividend Contender That Is Valued At A Premium

Summary Exponent Inc. is a market leader in scientific and engineering consulting, with a 13-year dividend growth streak and a solid balance sheet. Despite strong revenue and earnings growth, the valuation is at a premium, making Exponent a hold. The company's competitive advantages include its reputation, technical expertise, and long-term client relationships, ensuring continued market leadership. Exponent's dividend safety is excellent, supported by a conservative payout ratio and robust free cash flow, but the current valuation is a concern. Read the full article on Seeking Alpha
Artículo de análisis Feb 13

Exponent's (NASDAQ:EXPO) Shareholders Will Receive A Bigger Dividend Than Last Year

Exponent, Inc.'s ( NASDAQ:EXPO ) dividend will be increasing from last year's payment of the same period to $0.30 on...
Artículo de análisis Jan 30

Exponent, Inc.'s (NASDAQ:EXPO) Intrinsic Value Is Potentially 34% Above Its Share Price

Key Insights The projected fair value for Exponent is US$122 based on 2 Stage Free Cash Flow to Equity Exponent is...
Artículo de análisis Dec 28

Risks To Shareholder Returns Are Elevated At These Prices For Exponent, Inc. (NASDAQ:EXPO)

Exponent, Inc.'s ( NASDAQ:EXPO ) price-to-earnings (or "P/E") ratio of 42.7x might make it look like a strong sell...
Artículo de análisis Dec 10

Here's What To Make Of Exponent's (NASDAQ:EXPO) Decelerating Rates Of Return

If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...
Artículo de análisis Nov 08

Exponent's (NASDAQ:EXPO) Earnings Seem To Be Promising

Despite posting healthy earnings, Exponent, Inc.'s ( NASDAQ:EXPO ) stock has been quite weak. Along with the solid...
Artículo de análisis Oct 13

Estimating The Intrinsic Value Of Exponent, Inc. (NASDAQ:EXPO)

Key Insights Exponent's estimated fair value is US$114 based on 2 Stage Free Cash Flow to Equity Current share price of...
User avatar
Nueva narrativa Aug 29

Operational Efficiency And Tactical Investments Set To Propel Future Profitability And Revenue Growth

Exponent's strategic management and operational efficiency improvements are poised to enhance future profitability and earnings potential.

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Catherine Corrigan en comparación con los beneficios de Exponent?
FechaCompensación totalSalarioIngresos de la empresa
Apr 03 2026n/an/a

US$109m

Jan 02 2026US$4mUS$970k

US$106m

Oct 03 2025n/an/a

US$105m

Jul 04 2025n/an/a

US$103m

Apr 04 2025n/an/a

US$106m

Jan 03 2025US$3mUS$948k

US$109m

Sep 27 2024n/an/a

US$106m

Jun 28 2024n/an/a

US$105m

Mar 29 2024n/an/a

US$101m

Dec 29 2023US$4mUS$888k

US$100m

Sep 29 2023n/an/a

US$102m

Jun 30 2023n/an/a

US$102m

Mar 31 2023n/an/a

US$102m

Dec 30 2022US$4mUS$831k

US$102m

Sep 30 2022n/an/a

US$100m

Jul 01 2022n/an/a

US$100m

Apr 01 2022n/an/a

US$100m

Dec 31 2021US$3mUS$763k

US$101m

Oct 01 2021n/an/a

US$103m

Jul 02 2021n/an/a

US$96m

Apr 02 2021n/an/a

US$87m

Jan 01 2021US$3mUS$712k

US$83m

Oct 02 2020n/an/a

US$80m

Jul 03 2020n/an/a

US$81m

Apr 03 2020n/an/a

US$86m

Jan 03 2020US$3mUS$675k

US$82m

Compensación vs. Mercado: La compensación total de Catherine($USD3.74M) está por debajo de la media de empresas de tamaño similar en el mercado US ($USD6.90M).

Compensación vs. Ingresos: La compensación de Catherine ha sido consistente con los resultados de la empresa en el último año.


CEO

Catherine Corrigan (57 yo)

8.2yrs
Permanencia
US$3,736,574
Compensación

Dr. Catherine Ford Corrigan, Ph D., PE, serves as Chief Executive Officer and Director of Exponent, Inc. since May 31, 2018 and had been its President since July 29, 2016 until May 1, 2026. On February 9,...


Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Catherine Corrigan
CEO & Director8.2yrsUS$3.74m0.24%
$ 7.2m
Richard Schlenker
Executive VP28.7yrsUS$2.37m0.47%
$ 14.3m
Maureen T. Reitman
Group Vice President12.2yrsUS$1.83m0.077%
$ 2.3m
Joseph Rakow
Group Vice Presidentno dataUS$2.00m0%
$ 0
Joseph Sala
Group Vice Presidentno dataUS$1.66m0%
$ 0
John Pye
President20.5yrsUS$1.27m0.060%
$ 1.8m
Bernard Ross
Co-Founder & Principal Engineerno datasin datossin datos
Eric Anderson
Chief Financial Officerless than a yearsin datos0.0061%
$ 183.7k
Gina Flynn
VP of Legal & General Counselno datasin datossin datos
Brian Kundert
Chief Human Resources Officer2.3yrssin datossin datos
Akiyo Toba
Controllerno datasin datossin datos
Bradley James
Group Vice Presidentno dataUS$1.16m0.0023%
$ 68.8k
10.2yrs
Permanencia media
55yo
Promedio de edad

Equipo directivo experimentado: El equipo directivo de EXPO es experimentado (10.2 años antigüedad media).


Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Catherine Corrigan
CEO & Director8.2yrsUS$3.74m0.24%
$ 7.2m
Richard Schlenker
Executive VPless than a yearUS$2.37m0.47%
$ 14.3m
Debra Zumwalt
Independent Director12.2yrsUS$272.01k0.066%
$ 2.0m
Paul Johnston
Chairman Emeritusless than a yearUS$310.01k0.13%
$ 3.9m
George Brown
Independent Director5.8yrsUS$272.01k0.022%
$ 667.1k
Carol Lindstrom
Independent Director9.4yrsUS$262.01k0.019%
$ 584.8k
Karen Richardson
Independent Chairman3.4yrsUS$277.01k0.071%
$ 2.1m
5.8yrs
Permanencia media
68yo
Promedio de edad

Junta con experiencia: La junta directiva de EXPO se considera experimentada (5.8 años de antigüedad promedio).


Análisis de la empresa y estado de los datos financieros

DatosÚltima actualización (huso horario UTC)
Análisis de la empresa2026/07/10 05:38
Precio de las acciones al final del día2026/07/10 00:00
Beneficios2026/04/03
Ingresos anuales2026/01/02

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

PaqueteDatosMarco temporalEjemplo Fuente EE.UU. *
Finanzas de la empresa10 años
  • Cuenta de resultados
  • Estado de tesorería
  • Balance
Estimaciones del consenso de analistas+3 años
  • Previsiones financieras
  • Objetivos de precios de los analistas
Precios de mercado30 años
  • Precios de las acciones
  • Dividendos, escisiones y acciones
Propiedad10 años
  • Accionistas principales
  • Información privilegiada
Gestión10 años
  • Equipo directivo
  • Consejo de Administración
Principales avances10 años
  • Anuncios de empresas

* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también contamos con guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Exponent, Inc. está cubierta por 7 analistas. 4 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

AnalistaInstitución
Joseph ForesiBrean Capital Historical (Janney Montgomery)
Alexis HusebyD.A. Davidson & Co.
Tomohiko SanoJ.P. Morgan